OBSIDIAN THERAPEUTICS, INC. (OBX) EBITDA
OBSIDIAN THERAPEUTICS, INC. (OBX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$26.14M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$28.26M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | (m) | -$26.14M | (m) | (m) | (m) | (m) | (m) | (m) | $21.55M | (m) | $0.00 |
|---|
| 2025-06-30 | Reported | (m) | -$28.26M | (m) | (m) | (m) | (m) | (m) | (m) | $22.95M | (m) | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | (m) | -$105.67M | (m) | (m) | (m) | $73.00K | -$90.39M | (m) | $86.11M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | (m) | -$91.25M | (m) | (m) | (m) | $779.00K | -$75.00M | (m) | $73.19M | (m) | $0.00 |
|---|